The combination of a prolonged treatment time window and alpha-fetoprotein benefits the tumor response of hepatocellular carcinoma patients as evaluated by the imRECIST: a single-center, retrospective study

BACKGROUND: The combined immunotargeting therapy of hepatocellular carcinoma (HCC) have brought remarkable results. There are still some drawbacks to the application of the immune-modified Response Evaluation Criteria in Solid Tumors to Immunotherapy (imRECIST). How many weeks does it take to confir...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Kun-Li, Li, Ming, Liao, Rui, Shi, Zheng-Rong, Qiu, Jian-Guo, Lan, Xiang, Duan, Yu-Xin, Ye, Wen-Tao, Wu, Zhou-Yu, Du, Cheng-You, Xiao, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186499/
https://www.ncbi.nlm.nih.gov/pubmed/37201094
http://dx.doi.org/10.21037/jgo-23-167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186499/
https://www.ncbi.nlm.nih.gov/pubmed/37201094
http://dx.doi.org/10.21037/jgo-23-167

Ejemplares similares